Physician profile
Marc Wolfman
NPI 1174521355
$4,951.97
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,031 · 2020: $883 · 2021: $1,268 · 2022: $754 · 2023: $15.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,308.06 | 2019-2022 | |
| Abbvie INC. | $1,098.49 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $470.67 | 2019-2022 | |
| Janssen Biotech, INC. | $406.51 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $283.41 | 2019-2022 | |
| Pfizer INC. | $176.66 | 2019-2021 | |
| Allergan, INC. | $155.41 | 2019-2020 | |
| Daiichi Sankyo INC. | $128.53 | 2019-2022 | |
| Gilead Sciences, INC. | $109.27 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $99.01 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $97.44 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $92.81 | 2019-2022 | |
| Braintree Laboratories, INC. | $91.12 | 2019-2020 | |
| Redhill Biopharma INC. | $84.27 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $66.35 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $64.53 | 2019-2020 | |
| Celgene Corporation | $36.97 | 2022 | |
| Evoke Pharma, INC. | $35.93 | 2021 | |
| Ferring Pharmaceuticals INC. | $24.09 | 2019-2020 | |
| Vivus LLC | $17.23 | 2019 | |
| Ethicon US, LLC | $17.11 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $15.69 | 2023 | Exparel, Iovera |
| Qol Medical, LLC | $15.00 | 2022 | |
| Ardelyx, INC. | $14.90 | 2022 | |
| Shire North American Group INC | $14.32 | 2019 | |
| Shionogi INC | $14.31 | 2019 | |
| Alfasigma USA, INC. | $13.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Wolfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.